Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients. …
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 Australian Biotech
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News